GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » Cash per Share

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Cash per Share : ¥5.62 (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Shanghai Fosun Pharmaceutical (Group) Co's Cash per Share for the quarter that ended in Mar. 2024 was ¥5.62.


Shanghai Fosun Pharmaceutical (Group) Co Cash per Share Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Cash per Share Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.90 4.66 5.68 6.43 5.83

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.01 6.48 5.92 5.83 5.62

Shanghai Fosun Pharmaceutical (Group) Co Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Shanghai Fosun Pharmaceutical (Group) Co's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Shanghai Fosun Pharmaceutical (Group) Co's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Fosun Pharmaceutical (Group) Co  (SHSE:600196) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Shanghai Fosun Pharmaceutical (Group) Co Cash per Share Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Business Description

Traded in Other Exchanges
Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Headlines

No Headlines